Self-managed oral anticoagulation therapy

Marasinghe, Jeevan P.; Amarasinghe, A. A. W.
March 2007
CMAJ: Canadian Medical Association Journal;3/13/2007, Vol. 176 Issue 6, p813
Academic Journal
A letter to the editor is presented in response to the article "Cost effectiveness of self-managed versus physician managed oral anticoagulation therapy" by Dean Regier and others in the 2006 issue.


Related Articles

  • Self-managed oral anticoagulation therapy. Regier, Dean A.; Marra, Carlo A. // CMAJ: Canadian Medical Association Journal;3/13/2007, Vol. 176 Issue 6, p813 

    A response by the authors to a letter to the editor about their article "Cost effectiveness of self-managed versus physician managed oral anticoagulation therapy," in the 2006 issue is presented.

  • Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RAS-induced myeloproliferative disease. Sjogren, A.-K. M.; Andersson, K. M. E.; Khan, O.; Olofsson, F. J.; Karlsson, C.; Bergo, M. O. // Leukemia (08876924);Jan2011, Vol. 25 Issue 1, p186 

    A letter to the editor is presented which discusses a study regarding the impact of protein geranylgeranyltransferase type I (GGTase-I) on the growth of hematologic malignancies using mice as subjects.

  • Anemic and considered dangerous. Kaplan, B. // Current Health 2;Nov89, Vol. 16 Issue 3, p10 

    Discusses the different kinds of anemia and how they can be treated. Iron-deficiency anemia; Folic-acid deficiency anemia; B12-deficiency anemia; Sickle-cell anemia; Thalassemia.

  • Hemophilia.  // FDA Consumer;Jun84, Vol. 18 Issue 5, p18 

    Once known as the Royal Disease because it afflicted some European thrones, hemophilia is not just a blue blood's disease, but is a problem for others, including some 20,000 Americans. However, a less expensive and safer treatment may be in the wings for many of its victims.

  • Three products for hemophilia B.  // FDA Consumer;Dec92, Vol. 26 Issue 10, p2 

    Reports that three biological products were licensed by the Food and Drug Administration in August 1992 to prevent or control excessive bleeding from hemophilia B. What hemophilia B is; Bebulin VH, manufactured by Osterreichisches Institut fur Haemoderivate G.m.b.H., Vienna, Austria; Mononine,...

  • New treatment for hemophiliacs.  // FDA Consumer;Mar1993, Vol. 27 Issue 2, p3 

    Reports that the first genetically engineered clotting factor used to treat people with hemophilia A was licensed by the Food and Drug Administration in December 1992. What the product, antihemophilic factor (recombinant), does; What hemophilia A is; Recommendations of FDA's Blood Products...

  • Haemophiliacs' hope.  // New Scientist;2/1/92, Vol. 133 Issue 1806, p19 

    Reports that the British Technology Group and Genetic Therapy of Maryland have signed a worldwide agreement awarding Genetic Therapy the rights to develop gene therapy for treating hemophilia B. Affects 15 percent of hemophiliacs; How doctors treat this presently.

  • A less expensive way to monitor heparin therapy. Cerrato, Paul L. // RN;Jun93, Vol. 56 Issue 6, p19 

    Features low-range activated clotting time (LR-ACT), a bedside test that monitors the effects of heparin therapy, published in the American Journal of Critical Care; Previous method as time-consuming and expensive; Comparison of cost with activated partial thromboplastin time (aPTT).

  • Transfusion saves anemic babies.  // USA Today Magazine;Feb92, Vol. 120 Issue 2561, p6 

    Explains how the transfusion of blood into anemic fetuses via the umbilical cord is helping to save lives. Brief description of the procedure; When it is most often performed.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics